Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can access the webcast through the company's website, where a recorded version will be available shortly after the event and remain accessible for approximately 90 days.

Tarsus Pharmaceuticals (NASDAQ: TARS) is set to present four significant data sets at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting in Los Angeles from April 25-28, 2025. The presentations will focus on the global prevalence of Demodex blepharitis and the clinical impact of their treatment, XDEMVY® (lotilaner ophthalmic solution) 0.25%.

The four presentations include:

• The Orion Registry interim results on disease burden and treatment efficacy
• The Janus Study comparing symptoms and clinical outcomes
• Studies on XDEMVY's effectiveness in patients with Meibomian Gland Dysfunction
• The Elara Study on Demodex blepharitis prevalence in Japan

According to Dr. Elizabeth Yeu, Chief Medical Officer of Tarsus, these presentations will reinforce the global burden of Demodex blepharitis and demonstrate XDEMVY's potential to improve patient outcomes across multiple subtypes.

Tarsus Pharmaceuticals (TARS) has announced the pricing of an upsized public offering of 2,808,988 shares of its common stock at $44.50 per share. The company expects to raise approximately $125.0 million in gross proceeds before deducting underwriting costs and other expenses.

The offering includes a 30-day option for underwriters to purchase up to an additional 421,348 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 14, 2025.

Goldman Sachs & Co. , BofA Securities, Barclays, and Oppenheimer & Co. are serving as joint book-running managers for the offering.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced the launch of a $100.0 million underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional $15.0 million of shares.

The offering will be managed by joint book-running managers Goldman Sachs & Co. , BofA Securities, Barclays, and Oppenheimer & Co. All shares in the proposed offering will be sold by Tarsus, subject to market and other conditions. A registration statement for the offering was filed with the SEC on February 29, 2024, and became automatically effective upon filing.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its upcoming participation in the Barclays 27th Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, March 11th at 8:00 a.m. / 11:00 a.m. ET.

Interested parties can access a live webcast of the presentation through the events section of the Tarsus website. A replay of the session will be made available within 48 hours and will remain accessible for a time on the company's website.

Tarsus Pharmaceuticals reported strong financial results for Q4 and full-year 2024, with XDEMVY® generating $66.4 million in Q4 and $180.1 million in full-year net product sales during its first full year of launch. The company dispensed over 58,500 bottles in Q4 and 163,000 bottles throughout 2024.

Key achievements include establishing broad Eye Care Professional utilization across more than 15,000 target ECPs and securing commercial, Medicare, and Medicaid reimbursement covering over 90% of lives. Tarsus launched a Direct-To-Consumer campaign on streaming platforms in Q4 2024 and began network television trials in January 2025.

The company presented groundbreaking data showing XDEMVY is the first pharmacologic treatment demonstrating functional improvements in Meibomian Gland Disease. Tarsus continues advancing its pipeline, including TP-04 for Ocular Rosacea with a Phase 2 study planned for H2 2025, and TP-05 for Lyme disease prevention.

As of December 31, 2024, Tarsus had $291.4 million in cash, cash equivalents, and marketable securities, with a net loss of $23.1 million for Q4 and $115.6 million for the full year.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Tuesday, February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET to present its fourth quarter and full-year 2024 financial results along with a corporate update. The webcast will be available for participants to access online, and a recorded version will be posted on the company's website shortly after the event, remaining accessible for approximately 90 days.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its management team's upcoming participation in two major investor conferences in February 2025. The company will engage in fireside chats at:

• The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET

• The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET

Interested parties can access a live webcast through the events section of the Tarsus website. Replay recordings will be made available within 48 hours of each event and will remain accessible for a time.